Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
SEC Accession No. 0000921895-22-002078
Filing Date
2022-06-23
Accepted
2022-06-23 16:12:29
Documents
2

Document Format Files

Seq Description Document Type Size
1 dfan14a11375004_06232022.htm DFAN14A 53342
2 EXHIBIT 1 - AMENDMENT NO. 1 TO THE SCHEDULE 13D ex1todfan14a11375004_062322.pdf DFAN14A 331785
  Complete submission text file 0000921895-22-002078.txt   512280
Mailing Address 23046 AVENIDA DE LA CARLOTA, SUITE 600 LAGUNA HILLS CA 92653
Business Address 23046 AVENIDA DE LA CARLOTA, SUITE 600 LAGUNA HILLS CA 92653 (917) 595.2850
PharmaCyte Biotech, Inc. (Subject) CIK: 0001157075 (see all company filings)

EIN.: 621772151 | State of Incorp.: NV | Fiscal Year End: 0430
Type: DFAN14A | Act: 34 | File No.: 001-40699 | Film No.: 221035633
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 641 LEXINGTON AVENUE 26TH FLOOR NEW YORK, NY 10022
Business Address 641 LEXINGTON AVENUE 26TH FLOOR NEW YORK, NY 10022 212.974.3070
Iroquois Capital Management, LLC (Filed by) CIK: 0001481867 (see all company filings)

EIN.: 010786483 | State of Incorp.: DE
Type: DFAN14A